BELLUS HEALTH |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.48 CAD | -0.10% |
|
-.--% | -.--% |
| 2023 | BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Capped Composite Index | CI |
| 2023 | BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Completion Index | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
BELLUS Health Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (RCC). Camlipixant is a highly selective antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. It is being evaluated in the CALM phase III clinical development programmed. It is developing camlipixant for the treatment of adults with RCC. Camlipixant has the potential to address the significant unmet need for an efficacious, safe and well tolerated treatment for refractory chronic cough.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 1.87B | |
| -3.38% | 102B | |
| +1.64% | 96.07B | |
| -1.80% | 21.66B | |
| -18.01% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.00% | 13.79B | |
| -0.69% | 13.33B | |
| +19.21% | 10.94B |
- Stock Market
- Equities
- BLU Stock
- News BELLUS Health
- RBC Capital Markets Maintains BELLUS Health's Rating, Price Target
